SCHEMBL14800367

SCHEMBL14800367

c1ccc2c(c1)Cc1cc3cc4ccccc4cc3cc1C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP3A4 P08684 3/20 0.44
TSHR P16473 2/20 0.44
HSD17B10 Q99714 3/20 0.44
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
PKM P14618 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C19 P33261 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALOX15 P16050 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19810040 0.95 CYP1A2 (0.46) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL30376019 0.95 MEN1 (0.48) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL8662572 0.95 MEN1 (0.48) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL19810032 0.95 MEN1 (0.48) MEN1KMT2ACYP3A4TSHRHSD17B10
Anthracene SCHEMBL2876495 0.92 CYP3A4 (0.50) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL31274423 0.89 MEN1 (0.52) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL7914941 0.89 MEN1 (0.52) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL29604701 0.89 MEN1 (0.52) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL1808685 0.89 MEN1 (0.52) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL19810068 0.83 ESR1 (0.43) MEN1KMT2ACYP3A4TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10604469-B2 Method for the preparation of a partially hydrogenated polyacene and an intermediate thereof FUNDACIO INSTITUT CATALA D'INVESTIGACIO QUIMICA (ES) 2020-03-31 US disclosed
US-20190161426-A1 METHOD FOR THE PREPARATION OF A PARTIALLY HYDROGENATED POLYACENE AND AN INTERMEDIATE THEREOF UNIVERSITAT ROVIRA I VIRGILI (ES) 2019-05-30 US disclosed
WO-2018019436-A1 METHOD FOR THE PREPARATION OF A PARTIALLY HYDROGENATED POLYACENE AND AN INTERMEDIATE THEREOF FUNDACIÓ INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA (ICIQ) (ES) 2018-02-01 WO disclosed
EP-3275876-A1 METHOD FOR THE PREPARATION OF A PARTIALLY HYDROGENATED POLYACENE AND AN INTERMEDIATE THEREOF Fundació Institut Català D'investigació Quimica (ES) 2018-01-31 EP disclosed
US-8785671-B2 6,13-dihalogen-5,14-dihydropentacene derivative and method for producing 6,13-substituted-5,14-dihydropentacene derivative using same NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2014-07-22 US disclosed
US-20130079530-A1 6,13-DIHALOGEN-5,14-DIHYDROPENTACENE DERIVATIVE AND METHOD FOR PRODUCING 6,13-SUBSTITUTED-5,14-DIHYDROPENTACENE DERIVATIVE USING SAME NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY 2013-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079530-A1 6,13-DIHALOGEN-5,14-DIHYDROPENTACENE DERIVATIVE AND METHOD FOR PRODUCING 6,13-SUBSTITUTED-5,14-DIHYDROPENTACENE DERIVATIVE USING SAME DHCR7, DHCR24, DHPS MEN1 1611/4885KMT2A 1267/4885CYP3A4 182/4885
US-10604469-B2 Method for the preparation of a partially hydrogenated polyacene and an intermediate thereof PARN, PCBP1, PARG MEN1 973/4885KMT2A 528/4885CYP3A4 584/4885
US-20190161426-A1 METHOD FOR THE PREPARATION OF A PARTIALLY HYDROGENATED POLYACENE AND AN INTERMEDIATE THEREOF PARN, PCBP1, PARG MEN1 973/4885KMT2A 528/4885CYP3A4 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.